Skip to main content
Premium Trial:

Request an Annual Quote

Prolinx, BioDiscovery, Gyros, Hyseq, Molecular Mining, Nottingham Arabidopsis Stock Center

Premium

Prolinx and BioDiscovery Link up To Develop Protein Microarray Analysis Tool

 

Seizing on the emerging market for protein microarray analysis tools, Prolinx of Bothell, Wash., and BioDiscovery of Marina del Rey, Calif., have teamed up to develop an array analysis software tool.

Prolinx is bringing to the collaboration its knowledge of protein microarrays. The company markets a Versalinx protein array chemistry and slides to enable researchers to spot their own protein chips. BioDiscovery has developed GeneSight, a microarray analysis program for DNA arrays.

“This combination of expertise will maximize our customers’ analysis and enhance data quality to drive research and drug discovery development,” stated Jim Mahoney, president and CEO of Prolinx.

 

Gyros Spins Additional $6M into Funding Basket

 

Swedish compact disc microfluidics maker Gyros has raised an additional $6 million in second-round financing, bringing the total Series B financing to $36 Million.

The new financing was raised by Schroder Ventures Life Sciences, which is based in London, Boston, and San Francisco.

Gyros, an Uppsala-based spinoff of Amersham Pharmacia Biotech (now Amersham Biosciences) founded in 2000, has leveraged 10 years of AP Biotech research to develop what it calls “microlaboratories,” microfluidics devices that perform sample preparation and other steps of the experiment automatically, and allows hundreds of simultaneous analyses to be performed in parallel. The round shape of the devices allows minute samples to be distributed along a channel as the chip is spun.

The company began developing microfluidics-based protein chips in partnership with Affibody, of Stockholm, last May.

 

Hyseq Raises $15M in Private Stock Placement

 

Callida genomics’ parent company Hyseq Pharmaceuticals said last week it had raised about $15 million in a private stock placement.

Investors, which included new and existing institutional investors, bought roughly 3.6 million shares of newly issued common stock at $4.20 per share.

Hyseq said it also issued warrants to the investors to buy approximately 894,000 additional shares for $5.67 apiece, or a 35 percent premium to the per-unit purchase price.

 

Molecular Mining Opens US Headquarters, Launches New Software

 

Molecular Mining, the Kingston, Ontario, maker of the GeneLinker microarray data analysis software, has opened a new business headquarters in Cambridge, Mass., and launched the enhanced version of its software, GeneLinker Platinum.

The new headquarters will house the company’s US sales team and the sales, marketing, and business development staff.

“We are convinced that Cambridge puts us right at the center of one of the most vital areas in our markets,” Don Van Dyke, the company’s vice president of sales and marketing, said in a statement.

GeneLinker Platinum includes the Sub Linear Association Mining (SLAM) algorithm, a machine learning tool designed to quickly find high-order correlations and uncover the non-linear relationships involved in disease and drug response, the company said. This algorithm is not included in Molecular Mining’s initial microarray analysis program, GeneLinker Gold.

A white paper demonstrating the use of GeneLinker Platinum in a set of breast cancer gene expression data is available on the company’s website, http://www.molecularmining.com.

The company said it is planning to announce a partnership to provide hardware that goes along with this software soon.

 

Scientists Plant Arabidopsis Gene Expression Database: Affy Sprouts New Chips

 

Scientists at the Nottingham Arabidopsis Stock Center, a UK-based resource network for plant biology, have released a public web-based Arabidopsis gene expression database at the Society for Experimental Biology conference in Swansea, UK, April 12th.

The database, available at http://arabidopsis.info/prototype, includes data from Affymetrix Arabidopsis microarrays. This data is derived from experiments with the company’s 8,000 gene arrays at present, but will in the future include the results of work with Affymetrix’s new 24,000 gene Arabidopsis microarray, developed jointly with the Institute for Genomic Research.

TIGR re-annotated the Arabidopsis genome completed by the international Arabidopsis sequencing project as part of a collaboration with the US National Science Foundation, then collaborated with Affymetrix to use this information in developing a new higher-density Arabidopsis microarray.

“The substantial improvements TIGR made over the past year in Arabidopsis genome annotation are incorporated into this new array and will give scientists a powerful tool for a wide variety of plant studies,” stated Alan Dance, Affymetrix senior. vice president of corporate marketing. These arrays are being made to order, and are available in four weeks. Newly annotated Arabidopsis data is available on Affymetrix’s website.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.